A global healthcare company is set to host its inaugural ThinkLive Cell and Gene Therapy (CGT) Summit, bringing together leaders from the healthcare and biopharmaceutical industries. This two-day virtual event, commencing on May 14, aims to delve into the latest advancements in the CGT sector and strategies to expedite product commercialization and enhance patient access.
Featuring panel discussions and presentations, the summit will cover pivotal topics across the commercialization journey, spanning from clinical manufacturing and channel strategy to global launches and navigating the intricate supply chain requirements. Distinguished speakers will include experts from companies involved in CGT development and launch, alongside representatives from patient advocacy groups, trade associations, and regulatory bodies like the U.S. Food and Drug Administration (FDA).
Lung-I Cheng, Vice President and Head of Cell & Gene Therapy Service Line at Cencora, highlighted the complexities of the path to CGT commercialization and emphasized the summit’s objective of fostering collaboration and advancing best practices.
With nearly 2,000 CGT clinical trials underway globally and an anticipated 17 regulatory decisions on CGTs in the U.S. and Europe in 2024, the summit will address strategies to surmount barriers across the product lifecycle.
Cencora, renowned for its specialty distribution and services, provides comprehensive support to CGT developers, including logistics, regulatory consulting, market access, and patient support services. Through its CGT Integration Hub, Cencora aims to enhance visibility and streamline the therapy development and delivery process.
Willis Chandler, President of Global Pharma Services at Cencora, expressed optimism about the CGT market’s potential in the coming years and reaffirmed the company’s commitment to fostering a connected CGT ecosystem to unleash the full potential of these therapies.
